文献速递肿瘤 PET/CT

透明细胞肾细胞癌患者中[68Ga]Ga-P16-093与2-[18F]FDG PET/CT的头对头比较:一项先导研究

Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-01-05

这项先导研究前瞻性纳入42例病理确诊的透明细胞肾细胞癌(ccRCC)患者,每例在1周内先后接受[68Ga]Ga-P16-093与2-[18F]FDG PET/CT。原发灶和转移灶中,[68Ga]Ga-P16-093 PET/CT的检出率和肿瘤摄取均显著高于2-[18F]FDG PET/CT。结论认为[68Ga]Ga-P16-093 PET/CT对ccRCC患者的肿瘤可探测性显著优于2-[18F]FDG PET/CT。

要点

  • 原发ccRCC中[68Ga]Ga-P16-093检出19/22 vs 2-[18F]FDG 13/22,P=0.031
  • 转移性ccRCC中[68Ga]Ga-P16-093检出21/22 vs 2-[18F]FDG 14/22,P=0.008
  • 两种示踪剂原发灶SUVmax均与pT分期及WHO/ISUP分级显著相关

核心结论

  • 对于ccRCC患者,[68Ga]Ga-P16-093 PET/CT的肿瘤可探测性显著优于2-[18F]FDG PET/CT。

研究设计与样本

  • 这项先导研究为前瞻性设计,纳入42例病理确诊的ccRCC患者。
  • 每例患者在1周内先后接受[68Ga]Ga-P16-093与2-[18F]FDG PET/CT,并进行视觉分析和SUV半定量比较及相关分析。

主要发现

  • 原发ccRCC患者中,[68Ga]Ga-P16-093 PET/CT检出率19/22 vs 2-[18F]FDG PET/CT 13/22(P=0.031),肿瘤摄取15.7±9.0 vs 5.1±3.4(P<0.001)。
  • 原发灶[68Ga]Ga-P16-093 SUVmax与pT分期相关(r=0.550,P=0.008),2-[18F]FDG SUVmax与pT分期相关(r=0.514,P=0.014)。
  • 原发灶[68Ga]Ga-P16-093 SUVmax与WHO/ISUP分级相关(r=0.566,P=0.006),2-[18F]FDG SUVmax与WHO/ISUP分级相关(r=0.492,P=0.020)。
  • 转移性ccRCC患者中,[68Ga]Ga-P16-093 PET/CT检出率21/22 vs 2-[18F]FDG PET/CT 14/22(P=0.008),肿瘤摄取11.0±6.4 vs 4.4±2.7(P<0.001)。
  • [68Ga]Ga-P16-093 SUVmax与原发ccRCC中PSMA表达相关(r=0.776,P<0.001),与转移性ccRCC中PSMA表达相关(r=0.626,P=0.029)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This pilot study was prospectively designed to evaluate and compare the diagnostic value of PET/CT using a PSMA-specific tracer [68Ga]Ga-P16-093 and a glucose metabolism probe 2-[18F]FDG in clear cell renal cell carcinoma (ccRCC) patients. METHODS: Forty-two pathologically confirmed ccRCC patients were included. Within 1 week, each patient underwent [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT. In addition to visual analysis of tumor number, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. RESULTS: For primary ccRCC patients, [68Ga]Ga-P16-093 PET/CT demonstrated a significantly higher detection rate (19/22 vs. 13/22, P = 0.031) and higher tumor uptake (15.7 ± 9.0 vs. 5.1 ± 3.4, P < 0.001) than 2-[18F]FDG PET/CT. In addition, the SUVmax of the primary tumor on [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT was significantly correlated with pT stage (for [68Ga]Ga-P16-093, r = 0.550, P = 0.008; for 2-[18F]FDG, r = 0.514, P = 0.014) and WHO/ISUP grade (for [68Ga]Ga-P16-093, r = 0.566, P = 0.006; for 2-[18F]FDG, r = 0.492, P = 0.020), respectively. For metastatic ccRCC patients, [68Ga]Ga-P16-093 PET/CT also demonstrated a better detection rate (21/22 vs. 14/22, P = 0.008) and higher tumor uptake (11.0 ± 6.4 vs. 4.4 ± 2.7, P < 0.001) than 2-[18F]FDG PET/CT. The SUVmax on [68Ga]Ga-P16-093 PET/CT had a significant association with PSMA expression in primary ccRCC (r = 0.776, P < 0.001) and metastatic ccRCC (r = 0.626, P = 0.029). CONCLUSIONS: [68Ga]Ga-P16-093 PET/CT demonstrates significantly better tumor detectability than 2-[18F]FDG PET/CT for ccRCC patients. TRIAL REGISTRATION: 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients (NCT05432947, Registered 27 June 2021, retrospectively registered) URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05432947 .

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang G, Li L, Wang J, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023. PMID: 36600099. doi:10.1007/s00259-022-06101-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。